710351-82-9

Upstream product

• 710351-81-8 1-[2-(3-nitro-phenyl)-ethyl]-pyrrolidine 
• 945104-41-6 3-(2-oxo-2-pyrrolidin-1-ylethyl)aniline 
• 99-61-6 3-nitro-benzaldehyde 
• 444681-65-6 1,1-dibromo-2-(3-nitrophenyl)ethene 
• 19281-19-7 1-[(3-nitrophenyl)acetyl]pyrrolidine 

Downstream Products

• 710351-83-0 3-(2-pyrrolidinylethyl)benzeneisothiocyanate 
• 1023276-38-1 8-indan-5-yl-5-oxo-2-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid methoxy-amide 
• 945104-40-5 3-(4-tert-butylphenyl)-5,5-dimethyl-1-[(2-{[3-(2-pyrrolidin-1-ylethyl)phenyl]amino}pyridin-4-yl)-methyl]imidazolidine-2,4-dione 
• 891856-67-0 cyano-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E/Z))-ylidene]-acetic acid allyl ester 
• 891856-66-9 cyano-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E/Z))-ylidene]-acetic acid ethyl ester 

Relevant academic research and scientific papers

IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION

Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula (I).

Synthesis and biological evaluation of new 4β-anilino-4′-O- demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents

A series of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives were prepared and evaluated for their cytotoxicities against four human cancer cell lines including KB, KB/VCR, A549 and 95D. Most compounds showed better growth-inhibition activities against tested cell lines than that of etoposide (VP-16). Preliminary structure-activity relationships (SARs) were concluded and it indicated that the side chains substituted at 4β position of podophyllotoxin significantly influenced the cytotoxic activity, especially for the drug resistance profile. In vivo studies of compound 26c on highly metastatic human lung cancer xenograft in nude mice showed that it can significantly inhibit tumor growth with administrating by oral route.

Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors

Compounds of formula (I): wherein Ra, Rb, R, X1 and X2 are as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.

5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R101 and R200 are described in the specification.

Metasubstituted thiazolidinones, their manufacture and use as a drug

This invention involves thiazolidinone of general formula (I) and its creation and use as inhibitors of polo like kinase (PLK) for the treatment of various diseases.

Substituted benzazoles and methods of their use as inhibitors of Raf kinase

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.